<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-164562" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Primary Lateral Sclerosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaneko</surname>
            <given-names>Kyle</given-names>
          </name>
          <aff>Barrow Neurological Institute</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hoskin</surname>
            <given-names>Justin</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hodis</surname>
            <given-names>Brendan</given-names>
          </name>
          <aff>Boston University, Chobanian &#x00026; Avedisian School of Medicine/Boston Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kyle Kaneko declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Justin Hoskin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brendan Hodis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-164562.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary lateral sclerosis (PLS) is a selective upper motor neuron disorder characterized by insidious onset of symptoms in the absence of lower motor neuron involvement. This condition is a diagnosis of exclusion. Therefore, other causes of upper motor neuron dysfunction, including hereditary spastic paraplegia, must be ruled out.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;The clinical course of PLS is typically more prolonged and benign than that of amyotrophic lateral sclerosis (ALS).<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r2">[2]</xref>&#x000a0;PLS classically involves the lower limbs in a symmetric distribution, although heterogeneity exists with some patients presenting with bulbar onset of symptoms.<xref ref-type="bibr" rid="article-164562.r3">[3]</xref><xref ref-type="bibr" rid="article-164562.r4">[4]</xref>&#x000a0;</p>
        <p>Clinical symptoms include stiffness, bulbar symptoms (eg, difficulty speaking and swallowing), labile affect (ie, pseudobulbar affect), mild weakness, and balance and coordination difficulties. PLS is diagnosed after a detailed clinical history, physical exam, and diagnostic testing have excluded other causes. Electromyography (EMG) is often normal but can aid in differentiating PLS from ALS when lower motor neuron dysfunction is observed.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r2">[2]</xref>&#x000a0;Brain magnetic resonance imaging (MRI) may be normal but can show changes in the precentral gyrus or corticospinal tracts, although these findings are not specific to PLS.<xref ref-type="bibr" rid="article-164562.r5">[5]</xref><xref ref-type="bibr" rid="article-164562.r6">[6]</xref>&#x000a0;No cure or disease-modifying treatment has been established for PLS, and treatment is supportive with the primary goal of improving functional mobility.</p>
      </sec>
      <sec id="article-164562.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of PLS remains unclear and is thought to occur sporadically.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref> Some study results suggest a genetic component, with reported genes associated with pathogenic variants of PLS, including juvenile onset (<italic toggle="yes">ALS2</italic> and<italic toggle="yes">&#x000a0;ERLIN2</italic>) and adult-onset (<italic toggle="yes">C9orf72</italic>).<xref ref-type="bibr" rid="article-164562.r2">[2]</xref><xref ref-type="bibr" rid="article-164562.r7">[7]</xref>&#x000a0;Other genes of interest include <italic toggle="yes">PARK2</italic>, <italic toggle="yes">SYNE2</italic>, genes associated with HSP (eg, <italic toggle="yes">SPAST,</italic> SPG7, and<italic toggle="yes"> SPG11</italic>), and genes associated with ALS and frontotemporal dementia (eg, <italic toggle="yes">FIG4, OPTN, UBQLN2,</italic>
<italic toggle="yes">DCTN1</italic>, and<italic toggle="yes"> TBK1</italic>).<xref ref-type="bibr" rid="article-164562.r2">[2]</xref><xref ref-type="bibr" rid="article-164562.r8">[8]</xref>&#x000a0;Further studies are warranted to define the genetic contribution and pathophysiology of PLS.</p>
      </sec>
      <sec id="article-164562.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>PLS is predominantly a disorder in men with a man-to-woman ratio between 2:1 and 4:1, which represents about 2% to 3% of patients with motor neuron disease.<xref ref-type="bibr" rid="article-164562.r9">[9]</xref> The incidence is estimated at 0.1 per 100,00 per year.<xref ref-type="bibr" rid="article-164562.r2">[2]</xref><xref ref-type="bibr" rid="article-164562.r10">[10]</xref>&#x000a0;No differences in ethnicity have been reported.<xref ref-type="bibr" rid="article-164562.r2">[2]</xref><xref ref-type="bibr" rid="article-164562.r11">[11]</xref>&#x000a0;Symptoms typically start around the 5th to 6th decade of life, with the mean age of symptoms around 50 years, although heterogeneity exists.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Age of onset can help clinicians diagnose PLS as this is nearly a decade earlier than nonfamilial ALS and almost a decade earlier than HSP.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r4">[4]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-164562.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PLS is caused by dysfunction of the descending corticospinal tracts, although the precise molecular and cellular mechanisms remain unclear. PLS is a sporadic disease; only a small percentage of patients with clinically definite criteria for PLS will have identifiable pathological mutations.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;One mechanism of upper motor neuron dysfunction is intracellular trafficking problems due to the lack of expression of Alsin, a protein encoded by <italic toggle="yes">ALS2</italic>.<xref ref-type="bibr" rid="article-164562.r12">[12]</xref>&#x000a0;In mouse models, depletion of Alsin led to the disintegration of corticospinal tract neurons in the pons, pyramidal decussation, and cervical spinal cord.<xref ref-type="bibr" rid="article-164562.r13">[13]</xref>&#x000a0;Recessive loss-of-function mutations in&#x000a0;<italic toggle="yes">ALS2</italic>&#x000a0;have been seen in atypical forms of PLS, although these have also been seen in HSP.<xref ref-type="bibr" rid="article-164562.r2">[2]</xref>&#x000a0;Genetic knowledge regarding ALS, HSP, and PLS is still incomplete, and research is ongoing.</p>
      </sec>
      <sec id="article-164562.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>No pathognomonic histopathological changes are seen in PLS, but several changes are consistent with the diagnosis. These changes include chronic degeneration or loss of the white matter associated with the descending corticospinal tracts, absence of Betz cells, and degeneration of the primary motor cortex, with relative preservation of lower motor neurons.<xref ref-type="bibr" rid="article-164562.r14">[14]</xref>&#x000a0;Immunohistochemistry can show ubiquitin-immunoreactive neuronal cytoplasmic inclusion bodies in the motor cortex with mild or absent lower motor neuron involvement.<xref ref-type="bibr" rid="article-164562.r15">[15]</xref>&#x000a0;</p>
        <p>Ubiquitin-immunoreactive neuronal cytoplasmic inclusion bodies have also been detected in the hippocampus and prefrontal areas.<xref ref-type="bibr" rid="article-164562.r15">[15]</xref>&#x000a0;Transactive response deoxyribonucleic acid-binding protein of 43 kDa (TDP-43) inclusions can be seen in the primary motor cortex, corticospinal tract, hippocampus, and frontotemporal region of patients with PLS.<xref ref-type="bibr" rid="article-164562.r14">[14]</xref><xref ref-type="bibr" rid="article-164562.r15">[15]</xref>&#x000a0;Although rare, TDP-43 immunoreactive pathology was found in lower motor neurons but averaged less than 1 inclusion per tissue section.<xref ref-type="bibr" rid="article-164562.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-164562.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Clinical Features</bold>
</p>
        <p>PLS is predominantly found in men, with clinical onset usually in the 5th to 6th decade of life.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Symptom onset is insidious with slow progression, frequently involving the lower limbs first. A minority of patients can have bulbar onset with symptoms of dysarthria, dysphagia, nasal speech, and pseudobulbar affect.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r2">[2]</xref>&#x000a0;Symptoms of PLS include stiffness, poor coordination, balance difficulties, urinary frequency or urgency, and bulbar symptoms.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Early involvement of the lower limbs is often described as gait disturbances, mild weakness, or a loss of balance. The progression of symptoms is generally slow, spreading from side to side and from region to region, with the average symptom duration ranging from 7.2 to 14.5 years.<xref ref-type="bibr" rid="article-164562.r5">[5]</xref>&#x000a0;Progression is variable and seems to stop after several years. PLS differs from ALS in that the need for a feeding tube or permanent assisted ventilation is low at 7% and less than 1%, respectively.<xref ref-type="bibr" rid="article-164562.r16">[16]</xref>&#x000a0;</p>
        <p>Involvement of the lower limbs in PLS is most frequently symmetric, although rare phenotypes have been described. A rare phenotype known as the &#x0201c;hemiplegic variant&#x0201d; is characterized by slow progressive ascending weakness that begins in a distal lower limb and progresses to a proximal ipsilateral lower limb or upper limb, with associated pyramidal signs.<xref ref-type="bibr" rid="article-164562.r17">[17]</xref>&#x000a0;Bladder involvement described as increased frequency and possible retention is common in PLS and is seen in around 33% to 50% of patients.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref><xref ref-type="bibr" rid="article-164562.r11">[11]</xref>&#x000a0;Cognitive impairment can also be observed within the spectrum of frontotemporal dementia and frontal lobe dysfunction (executive function), although not as commonly as in ALS.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r2">[2]</xref><xref ref-type="bibr" rid="article-164562.r18">[18]</xref>&#x000a0;Neuropsychiatric manifestations in PLS include deficits in social cognition, motivation, verbal fluency, and executive dysfunction.<xref ref-type="bibr" rid="article-164562.r3">[3]</xref><xref ref-type="bibr" rid="article-164562.r19">[19]</xref></p>
        <p>Physical examination&#x000a0;reveals selective upper motor neuron (UMN) dysfunction, including hyperreflexia (eg, Hoffman sign and extensor toe responses), spasticity, or clonus. A UMN&#x000a0; pattern of weakness may also be seen, for example, in extensors in the upper extremities and flexors in the lower extremities. No sensory symptoms or lower motor neuron (LMN) signs (eg, fasciculations and muscle atrophy) should be present unless explained by another comorbid condition. Stiffness is seen more frequently as a presenting symptom in PLS compared to ALS (47% versus 4%).<xref ref-type="bibr" rid="article-164562.r14">[14]</xref>&#x000a0;Weakness described by the patient is often due to a combination of stiffness, increased tone, and reduced coordination rather than true muscle weakness. Abnormalities in ocular movements may also be seen, including the loss of smooth pursuit, issues with fixation, and supranuclear palsy.<xref ref-type="bibr" rid="article-164562.r20">[20]</xref></p>
        <p><bold>Diagnostic Criteria</bold>&#x000a0;</p>
        <p>The 2020 consensus diagnostic criteria for PLS include age older than 25, symptoms of progressive UMN dysfunction for at least 2 years involving at least 2 of 3 regions (ie, lower extremity, upper extremity, or bulbar), and the absence of sensory symptoms unexplained by a comorbid condition, active LMN degeneration, or an alternative diagnosis that better explains symptoms.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref> Diagnostic certainty was introduced with the new diagnostic criteria and can be further characterized as probable PLS or definite PLS. Probable PLS is defined by the absence of significant active LMN degeneration at 2 to 4 years, and definite PLS is defined as more than 4 years from symptom onset. The probable PLS category aims to enroll patients with PLS earlier in clinical trials for possible disease-modifying treatment before disability becomes advanced. Clinical disability can be evaluated using the revised ALS Functional Rating Scale, Penn Upper Motor Neuron Score, the Modified Ashworth Scale, or the PLS functional rating scale.<xref ref-type="bibr" rid="article-164562.r21">[21]</xref></p>
      </sec>
      <sec id="article-164562.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>No diagnostic test can definitively diagnose PLS, as this condition is a clinical diagnosis that requires obtaining a thorough clinical history and family history and performing a comprehensive physical examination. Laboratory and diagnostic studies are used to rule out alternative causes of UMN dysfunction in the brain or spinal cord.&#x000a0;</p>
        <p><bold>Laboratory Studies</bold>&#x000a0;</p>
        <p>Laboratory studies that exclude alternative differential diagnoses include vitamin B12, copper, human immunodeficiency virus, human T lymphotropic virus I/II, Lyme disease (in certain cases), cerebrospinal fluid (CSF) evaluation, and paraneoplastic panels.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Neurofilaments are an emerging biomarker that reflects and quantifies neuronal loss. These levels tend to be much lower in PLS than in ALS, but differences between UMN-predominant ALS and PLS warrant further studies.<xref ref-type="bibr" rid="article-164562.r22">[22]</xref>&#x000a0;CSF chitinases are another potential biomarker lower in PLS than in ALS. However, additional studies in larger cohorts and PLS versus UMN-predominant ALS are needed.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref><xref ref-type="bibr" rid="article-164562.r23">[23]</xref>&#x000a0;</p>
        <p>
<bold>Electromyography</bold>
</p>
        <p>A diagnostic challenge in PLS is differentiating it from UMN-predominant ALS, especially in patients that present in the early phase of the disease. Further complicating diagnosis, the EMG in patients with PLS can sometimes show minor LMN changes, including sparse fibrillations usually limited to 1 or 2 muscles, fasciculations, and enlarged motor unit potentials.<xref ref-type="bibr" rid="article-164562.r5">[5]</xref><xref ref-type="bibr" rid="article-164562.r24">[24]</xref>&#x000a0;Minimally increased insertional activity and positive sharp waves or fibrillation potentials in extremity muscles are permitted in the diagnostic criteria for PLS.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref>&#x000a0;Electromyogram (EMG) findings that show mild and nonprogressive LMN involvement are tolerated in the probable PLS category.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref>&#x000a0;A normal EMG with minimal denervation not fulfilling the El Escorial criteria for ALS is also needed to diagnose PLS. After 4 years, the probability of developing new LMN changes on EMG is low, around 20%.<xref ref-type="bibr" rid="article-164562.r15">[15]</xref>&#x000a0;Because of this, after 4 years from symptoms onset, probable PLS is defined as definite PLS.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref></p>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>MRI of the brain and spinal cord must be negative for alternative causes of UMN symptoms, although atrophy of the precentral gyrus is allowed.<xref ref-type="bibr" rid="article-164562.r7">[7]</xref>&#x000a0;Brain MRI can sometimes be helpful and show focal &#x0201c;knife edge&#x0201d; atrophy of the precentral gyrus and T2 hyperintensities in the corticospinal tracts thought to be secondary from Wallerian degeneration; these changes are not specific to PLS.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref><xref ref-type="bibr" rid="article-164562.r6">[6]</xref>&#x000a0;Corpus callosum, brainstem, and cerebellar abnormalities can also be seen.<xref ref-type="bibr" rid="article-164562.r3">[3]</xref><xref ref-type="bibr" rid="article-164562.r25">[25]</xref><xref ref-type="bibr" rid="article-164562.r26">[26]</xref>&#x000a0;Significant diffusivity alterations in the superior cerebellar peduncle have been noted in PLS, which suggests cerebro-cerebellar pathway disruption likely contributing to the motor and coordination disability seen in PLS.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref>&#x000a0;The presence of a &#x0201c;stripe sign&#x0201d; or focal fluorodeoxyglucose hypometabolism in the precentral gyrus has also been associated with PLS but is not a differentiating feature from ALS.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref><xref ref-type="bibr" rid="article-164562.r27">[27]</xref></p>
        <p>
<bold>Additional Diagnostic Studies</bold>
</p>
        <p>Transcranial magnetic stimulation (TMS) is a neurophysiological test that can quantify UMN dysfunction and may be helpful in the diagnosis of PLS. In patients with PLS, TMS shows longer central motor conduction times, higher cortical threshold, and absence of reproducible cortical responses in PLS compared to ALS.<xref ref-type="bibr" rid="article-164562.r24">[24]</xref><xref ref-type="bibr" rid="article-164562.r28">[28]</xref>&#x000a0;Cortical excitability is also preserved in HSP, helping differentiate HSP from PLS using TMS.<xref ref-type="bibr" rid="article-164562.r29">[29]</xref>&#x000a0;TMS has the potential to aid in the diagnosis of PLS, but this technology is not widely available.&#x000a0;</p>
        <p>Genetic testing can be helpful in complex cases and is usually performed in patients with symmetric progressive UMN involvement restricted to the lower limbs to differentiate PLS from HSP. HSP has over 50 different genes described, with the most common dominant and recessive forms secondary to mutations in <italic toggle="yes">SPG4</italic> (spastin) and <italic toggle="yes">SPG11</italic> (spatacsin), respectively. Additional testing for the <italic toggle="yes">C9orf72</italic> mutation can also be done if there is a high suspicion of UMN-predominant ALS, although this mutation can sometimes occur in PLS.<xref ref-type="bibr" rid="article-164562.r13">[13]</xref></p>
      </sec>
      <sec id="article-164562.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Currently, no cure or disease-modifying treatment for PLS has been identified.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Treatment is centered on symptom management and improving the quality of life in patients with PLS. Given the numerous symptoms seen in PLS, an interprofessional approach should be taken to improve mobility, reduce spasticity, and facilitate activities of daily living. Physical and occupational therapy are vital in improving gait and balance and can help determine the need for additional durable medical equipment. Speech therapy can be helpful in those with bulbar symptoms who have dysphagia or speech difficulties. Spasticity is often the most disabling symptom, and first-line oral agents include baclofen, benzodiazepines, and tizanidine. Patients who have sedating adverse events from these agents but have benefits may trial intrathecal baclofen and subsequent baclofen pump placement. Botulinum toxin type A can also be used to treat spasticity.<xref ref-type="bibr" rid="article-164562.r30">[30]</xref></p>
        <p>Anticholinergics are used to manage excessive secretions similar to ALS. Examples include glycopyrrolate, scopolamine, or atropine drops. In select patients who do not respond to oral medications, botulinum toxin injection into the submandibular gland can be helpful. Cognitive and neuropsychological features can be seen in PLS, and cognitive screening tests should be implemented in patients with PLS to assess for possible frontotemporal dysfunction, language deficits, and problems with executive function.<xref ref-type="bibr" rid="article-164562.r3">[3]</xref>&#x000a0;Formal neuropsychological testing should be done in patients who perform poorly on these cognitive screening tests.&#x000a0;</p>
        <p>Pseudobulbar affect is commonly seen in PLS, and recognition with screening and early treatment with medications can reduce social withdrawal and positively impact patients' quality of life. Treatment with dextromethorphan/quinidine is commonly used. In patients who cannot tolerate dextromethorphan/quinidine or do not benefit from treatment, amitriptyline or fluvoxamine can be trialed. However, neither has been studied in controlled trials for the pseudobulbar effect.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref>&#x000a0;Screening for mood symptoms, especially depression, is essential, and early referral to a psychiatrist or therapist is recommended when appropriate.&#x000a0;Riluzole, a Food and Drug Administration-approved drug for ALS that provides a modest survival benefit of a few months, has not shown survival benefits in patients with PLS and is currently not recommended in the treatment of PLS.<xref ref-type="bibr" rid="article-164562.r1">[1]</xref></p>
      </sec>
      <sec id="article-164562.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of PLS includes neurodegenerative, neuroinflammatory, metabolic, infectious, structural, and vascular etiologies. Neurodegenerative conditions to consider include UMN-predominant ALS, HSP, and Alexander disease. Upper motor neuron-predominant ALS can be difficult to distinguish between PLS given similar initial clinical symptoms. The development of clinically progressive lower motor neuron involvement helps distinguish UMN-predominant ALS from PLS, although this may develop years after initial presentation. Features that are more common in UMN-predominant ALS compared to PLS include a bulbar onset of symptoms, weight loss, medical research council grade less than 4 on the initial visit, and reduced forced vital capacity.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref><xref ref-type="bibr" rid="article-164562.r31">[31]</xref></p>
        <p>HSP and PLS have considerable clinical overlap, making distinguishing these diagnoses difficult. Both can have early onset lower limb involvement with marked UMN dysfunction. However, HSP usually has symmetrical weakness limited to the lower extremities rather than PLS, which can involve both the upper and lower extremities. A family history or relevant genetic variants is also seen in HSP, with up to 70 genetic variants recognized so far.<xref ref-type="bibr" rid="article-164562.r8">[8]</xref>&#x000a0;More common autosomal dominant forms of HSP will present in the second to third decade of life, while PLS mainly occurs in the fifth to sixth decade. The presence of a family history is more suggestive of HSP, as PLS is considered a sporadic disease. Other features that favor HSP include diminished vibratory sensation on physical exam, slower disease progression, absence of bulbar involvement, and earlier and symmetric onset of the disease.<xref ref-type="bibr" rid="article-164562.r4">[4]</xref><xref ref-type="bibr" rid="article-164562.r32">[32]</xref>&#x000a0;Given the significant heterogeneity in PLS, genetic testing remains essential for diagnosing PLS and ruling out HSP.&#x000a0;</p>
        <p>Neuroinflammatory conditions that can present similarly to PLS include primary progressive multiple sclerosis (PPMS) and stiff person spectrum disorder. PPMS is easily differentiated from PLS, with MRI showing inflammatory brain and spinal cord lesions. Stiff person spectrum disorder can present similarly but is distinguished through antibodies (eg, glutamic acid decarboxylase&#x000a0;65-kilodalton isoform, amphiphysin, glycine receptor, and dipeptidyl-peptidase-like protein 6) found in the serum or CSF. In seronegative cases with high suspicion for stiff person spectrum disorder, EMG can be helpful, showing co-contraction of agonist and antagonist muscles with continuous motor unit activity on insertion. Progressive solitary sclerosis is a rare disorder that can present with symmetrical and unilateral UMN dysfunction with progressive motor impairment that is considered a localized variant of multiple sclerosis. A single demyelinating lesion with oligoclonal bands in the cerebrospinal fluid is present in the central nervous system.<xref ref-type="bibr" rid="article-164562.r33">[33]</xref></p>
        <p>Metabolic conditions that can present similarly to PLS include adrenomyeloneuropathy and deficiencies of copper and of vitamins such as B12 and E.<xref ref-type="bibr" rid="article-164562.r34">[34]</xref> In its most severe form, vitamin B12 deficiency presents with subacute combined degeneration affecting the corticospinal tracts and the dorsal columns. Copper and vitamin E deficiencies can present similarly to myelopathies with or without sensory involvement. Copper deficiency is often seen in patients taking zinc supplementation or those with a history of bariatric surgery. Vitamin E is fat-soluble, and fat malabsorption conditions can lead to deficiencies. Examples of these conditions include Crohn disease, cystic fibrosis, cholestatic hepatobiliary disease, and exocrine pancreatic insufficiency.</p>
        <p>Nutrition labs should be checked since these conditions have significant clinical heterogeneity. Adrenomyeloneuropathy is an uncommon, inherited, slowly progressive disorder that affects the spinal cord. Diagnostics can show elevated blood levels of adrenocorticotropic hormone, elevated serum very long chain fatty acids, brain MRI white matter abnormalities, and mutations in the <italic toggle="yes">ABCD1</italic> gene.</p>
        <p>A few infectious etiologies can present similarly to PLS. Syphilis can present with myelopathy and UMN signs, although classically, it presents as tabes dorsalis with dorsal column involvement. Serologic and CSF testing for venereal disease can help distinguish neurosyphilis from PLS.&#x000a0;Human T-lymphotropic<bold>&#x000a0;</bold>viruses (HTLV) I/II can present with myelopathy and a normal neuroaxis MRI mimicking PLS. Clinical history can help diagnose HTLV as it is endemic to southwestern Japan, the Caribbean, South America, and sub-Saharan Africa. Serologic and CSF testing for HTLV antibodies confirms the diagnosis of HTLV-associated myelopathy.<xref ref-type="bibr" rid="article-164562.r34">[34]</xref></p>
        <p>Structural lesions that present similarly to PLS include foramen magnum lesions, syringomyelia, parafalcine meningioma, spinal cord tumors, or spinal cord compression, which are seen on MRI and easily separated from PLS. Vascular abnormalities, including ischemic lesions or spinal arteriovenous malformations, can also lead to myelopathies and are usually seen on MRI if large enough. Magnetic resonance angiography or a digital subtraction angiography is sometimes needed if gadolinium-enhanced MRI cannot visualize the vascular malformation.<xref ref-type="bibr" rid="article-164562.r34">[34]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-164562.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with PLS often have a benign clinical course with a more prolonged survival compared to patients with ALS. Patients with PLS are frequently concerned about possible progression to ALS. Most patients with UMN-predominant ALS will develop LMN signs or EMG changes within 4 years of symptoms onset.<xref ref-type="bibr" rid="article-164562.r35">[35]</xref><xref ref-type="bibr" rid="article-164562.r36">[36]</xref>&#x000a0;Patients with selective UMN involvement who do not develop LMN involvement after 4 years typically remain with pure UMN involvement and have a normal lifespan.<xref ref-type="bibr" rid="article-164562.r15">[15]</xref><xref ref-type="bibr" rid="article-164562.r35">[35]</xref><xref ref-type="bibr" rid="article-164562.r37">[37]</xref>&#x000a0;</p>
        <p>The progression of symptoms is variable but generally slow, with the average symptom duration ranging from 7.2 to 14.5 years.<xref ref-type="bibr" rid="article-164562.r5">[5]</xref>&#x000a0;PLS differs from ALS in that the need for a feeding tube or permanent assisted ventilation is low at 7% and less than 1%, respectively.<xref ref-type="bibr" rid="article-164562.r16">[16]</xref>&#x000a0;Although PLS is usually not life-shortening, it carries a significant disease burden, often from refractory spasticity.</p>
      </sec>
      <sec id="article-164562.s11" sec-type="Complications">
        <title>Complications</title>
        <p>PLS can have various clinical manifestations but often leads to similar complications. The most frequent complications seen in PLS include movement issues and falls secondary to gait impairment, balance difficulties, and weakness. Other complications include swallowing difficulties, speech changes, bladder problems (eg, frequency or retention), and pseudobulbar affect. Given the progressive and irreversible nature of the disease, mood symptoms like depression are frequently seen in patients with PLS.</p>
      </sec>
      <sec id="article-164562.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Diagnosis of PLS is challenging, given its rarity and clinical overlap with many other neurological diseases. PLS also lacks a gold standard diagnostic test or biomarker; thus, diagnosis is made clinically and by excluding other etiologies. Clinicians should consider PLS in patients with slowly progressive spasticity, stiffness, mild weakness, or corticobulbar signs. A comprehensive physical exam with particular attention to muscular strength and reflexes should be done. Hyperreflexia and corticobulbar signs may confuse clinicians with UMN-predominant ALS, and EMG is essential for complex cases. Patients with PLS should be educated on the progressive and unrecoverable nature of the disease with the understanding that treatment is only supportive.</p>
      </sec>
      <sec id="article-164562.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key factors that should be kept in mind regarding PLS include:</p>
        <list list-type="bullet">
          <list-item>
            <p>PLS is a chronic and slowly progressive neurodegenerative disease characterized by selective UMN involvement.</p>
          </list-item>
          <list-item>
            <p>The most common clinical features include spasticity, balance difficulties, corticobulbar signs, and mild weakness.</p>
          </list-item>
          <list-item>
            <p>PLS is a diagnosis of exclusion, made through a detailed clinical history and physical exam while ruling out other etiologies with diagnostic testing.</p>
          </list-item>
          <list-item>
            <p>No cure or disease-modifying therapy for PLS has been established; treatment is supportive and centered around improving functional mobility and quality of life.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-164562.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effectively managing PLS requires a comprehensive, interprofessional approach involving close collaboration among clinicians, nurses, pharmacists, and other healthcare professionals. This interdisciplinary team includes the patient's primary care clinician, neurologist, physical and occupational therapists, speech therapists, respiratory therapists, psychiatrists, and psychotherapists. Each member is critical in enhancing patient-centered care, safety, and outcomes.</p>
        <p>Physical and occupational therapists work to improve mobility and balance and reduce the risk of falls, often determining the need for durable medical equipment to support daily living. Speech therapists address bulbar symptoms, such as difficulties with speech and swallowing, while respiratory therapists monitor and manage breathing complications. Psychiatrists and mental health professionals are essential in screening for and managing depression, mood symptoms, and caregiver stress, providing emotional support to both patients and their families. Coordinating care and fostering clear communication between all team members ensures comprehensive symptom management, improves quality of life, and supports the progressive nature of PLS. This collaborative effort enhances team performance and optimizes patient safety by addressing the complex needs of patients with PLS.</p>
      </sec>
      <sec id="article-164562.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=164562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=164562">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/164562/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=164562">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-164562.s16">
        <title>References</title>
        <ref id="article-164562.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dimachkie</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary Lateral Sclerosis.</article-title>
            <source>Neurol Clin</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>749</fpage>
            <page-range>749-60</page-range>
            <pub-id pub-id-type="pmid">26515619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vacchiano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bonan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liguori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Primary Lateral Sclerosis: An Overview.</article-title>
            <source>J Clin Med</source>
            <year>2024</year>
            <month>Jan</month>
            <day>19</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38276084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bede</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pradat</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Lope</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vourc'h</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blasco</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Corcia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Primary Lateral Sclerosis: Clinical, radiological and molecular features.</article-title>
            <source>Rev Neurol (Paris)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>178</volume>
            <issue>3</issue>
            <fpage>196</fpage>
            <page-range>196-205</page-range>
            <pub-id pub-id-type="pmid">34243936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Corcia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ravits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Statland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <collab>Delegates of the 2nd International PLS Conference</collab>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: consensus diagnostic criteria.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>91</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-377</page-range>
            <pub-id pub-id-type="pmid">32029539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis.</article-title>
            <source>Muscle Nerve</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-302</page-range>
            <pub-id pub-id-type="pmid">17212349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finegan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chipika</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Shing</surname>
                <given-names>SLH</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bede</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: a distinct entity or part of the ALS spectrum?</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2019</year>
            <month>May</month>
            <volume>20</volume>
            <issue>3-4</issue>
            <fpage>133</fpage>
            <page-range>133-145</page-range>
            <pub-id pub-id-type="pmid">30654671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Gennings</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Hupf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Singleton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Nations</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shoesmith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kasarskis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Factor-Litvak</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Phenotypic and molecular analyses of primary lateral sclerosis.</article-title>
            <source>Neurol Genet</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>e3</fpage>
            <pub-id pub-id-type="pmid">27066542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Boer</surname>
                <given-names>EMJ</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Pennings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kamsteeg</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Veldink</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>van Es</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Genetic characterization of primary lateral sclerosis.</article-title>
            <source>J Neurol</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>270</volume>
            <issue>8</issue>
            <fpage>3970</fpage>
            <page-range>3970-3980</page-range>
            <pub-id pub-id-type="pmid">37133535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Heiman-Patterson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huey</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Statland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The clinical spectrum of primary lateral sclerosis.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>sup1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">33602013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcel&#x000f3;</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Povedano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Costa</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Franquet</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Solans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>6207</fpage>
            <pub-id pub-id-type="pmid">33737526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kojan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Herbelin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nations</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wolfe</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: clinical and laboratory features in 25 patients.</article-title>
            <source>J Clin Neuromuscul Dis</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">19078775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozdinler</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gozutok</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Konrad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Area Gomez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erb</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haase</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Better understanding the neurobiology of primary lateral sclerosis.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>sup1</issue>
            <fpage>35</fpage>
            <page-range>35-46</page-range>
            <pub-id pub-id-type="pmid">33602014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jara</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sekerkova</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yasvoina</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Martina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;zdinler</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms.</article-title>
            <source>Hum Mol Genet</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1074</fpage>
            <page-range>1074-87</page-range>
            <pub-id pub-id-type="pmid">26755825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackenzie</surname>
                <given-names>IRA</given-names>
              </name>
              <name>
                <surname>Briemberg</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>TDP-43 pathology in primary lateral sclerosis.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>sup1</issue>
            <fpage>52</fpage>
            <page-range>52-58</page-range>
            <pub-id pub-id-type="pmid">32657153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Kakita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piao</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kikugawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: a rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? Report of an autopsy case and a review of the literature.</article-title>
            <source>Acta Neuropathol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>615</fpage>
            <page-range>615-20</page-range>
            <pub-id pub-id-type="pmid">12734667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paganoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Marchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thrower</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Staff</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Datta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kisanuki</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Drory</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pioro</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Goutman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Atassi</surname>
                <given-names>N</given-names>
              </name>
              <collab>NEALS PLS Registry Study Group</collab>
              <name>
                <surname>Jeon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mcdonough</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denny</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Felice</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scarberry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abu-Saleh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nefussy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Swihart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arcila-Londono</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Genge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salmon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mccluskey</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Almasy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gotkine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goslin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Rivner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Quarles</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jaffa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baloh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allred</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maiser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manousakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ferment</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>JAM</given-names>
              </name>
              <name>
                <surname>Thaisetthawatkul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heimes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sams</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kahler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corcoran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larriviere</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Chotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Juba</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The NEALS primary lateral sclerosis registry.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>sup1</issue>
            <fpage>74</fpage>
            <page-range>74-81</page-range>
            <pub-id pub-id-type="pmid">32915077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigamonti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lauria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Agostoni</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Mills' syndrome: an Italian case and revision of the literature.</article-title>
            <source>Neurol Sci</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-6</page-range>
            <pub-id pub-id-type="pmid">22350219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caselli</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Osborne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: a neuropsychological study.</article-title>
            <source>Neurology</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>2005</fpage>
            <page-range>2005-9</page-range>
            <pub-id pub-id-type="pmid">7501149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finegan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shing</surname>
                <given-names>SLH</given-names>
              </name>
              <name>
                <surname>Chipika</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hengeveld</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Vajda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Donaghy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hardiman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bede</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Extra-motor cerebral changes and manifestations in primary lateral sclerosis.</article-title>
            <source>Brain Imaging Behav</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>2283</fpage>
            <page-range>2283-2296</page-range>
            <pub-id pub-id-type="pmid">33409820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringle</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Ebers</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria.</article-title>
            <source>Brain</source>
            <year>1992</year>
            <month>Apr</month>
            <volume>115 ( Pt 2)</volume>
            <fpage>495</fpage>
            <page-range>495-520</page-range>
            <pub-id pub-id-type="pmid">1606479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chiuzan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gilmore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Paganoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kisanuki</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jawdat</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sorenson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Pioro</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Fernandes Filho</surname>
                <given-names>JAM</given-names>
              </name>
              <name>
                <surname>Heitzman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Oskarsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heiman-Patterson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maragakis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nations</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scelsa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Walk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hupf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McHale</surname>
                <given-names>B</given-names>
              </name>
              <collab>PLSFRS study group</collab>
            </person-group>
            <article-title>Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale.</article-title>
            <source>Muscle Nerve</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-172</page-range>
            <pub-id pub-id-type="pmid">31758557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zucchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bedin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martinelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gianferrari</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sorar&#x000f9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liguori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vacchiano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mandrioli</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement.</article-title>
            <source>Biomedicines</source>
            <year>2021</year>
            <month>Nov</month>
            <day>05</day>
            <volume>9</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34829852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verde</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zaina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bodio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Soranna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peverelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ticozzi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doretti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maderna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Colombrita</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gumina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tiloca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Zambon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ratti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silani</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-223</page-range>
            <pub-id pub-id-type="pmid">32855294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuipers-Upmeijer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Jager</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hew</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Snoek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>van Weerden</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>615</fpage>
            <page-range>615-20</page-range>
            <pub-id pub-id-type="pmid">11606672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwata</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Danielian</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Butman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tovar-Moll</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bayat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis.</article-title>
            <source>Brain</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>Pt 9</issue>
            <fpage>2642</fpage>
            <page-range>2642-55</page-range>
            <pub-id pub-id-type="pmid">21798965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Unrath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huppertz</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ludolph</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neuroanatomical patterns of cerebral white matter involvement in different motor neuron diseases as studied by diffusion tensor imaging analysis.</article-title>
            <source>Amyotroph Lateral Scler</source>
            <year>2012</year>
            <month>May</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-64</page-range>
            <pub-id pub-id-type="pmid">22409361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Claassen</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Peller</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The stripe of primary lateral sclerosis: focal primary motor cortex hypometabolism seen on fluorodeoxyglucose F18 positron emission tomography.</article-title>
            <source>Arch Neurol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>122</fpage>
            <page-range>122-5</page-range>
            <pub-id pub-id-type="pmid">20065142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Carvalho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pullman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rezania</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Neurophysiological features of primary lateral sclerosis.</article-title>
            <source>Amyotroph Lateral Scler Frontotemporal Degener</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>sup1</issue>
            <fpage>11</fpage>
            <page-range>11-17</page-range>
            <pub-id pub-id-type="pmid">33602011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geevasinga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sue</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yiannikas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vucic</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia.</article-title>
            <source>Eur J Neurol</source>
            <year>2015</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>826</fpage>
            <page-range>826-31, e57-8</page-range>
            <pub-id pub-id-type="pmid">25683471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marvulli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Megna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Citraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ianieri</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis.</article-title>
            <source>Toxins (Basel)</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>11</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">31266172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.</article-title>
            <source>Neurology</source>
            <year>2009</year>
            <month>Jun</month>
            <day>02</day>
            <volume>72</volume>
            <issue>22</issue>
            <fpage>1948</fpage>
            <page-range>1948-52</page-range>
            <pub-id pub-id-type="pmid">19487653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fullam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Statland</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia.</article-title>
            <source>Brain Sci</source>
            <year>2021</year>
            <month>May</month>
            <day>11</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">34064596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giacopuzzi Grigoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cinnante</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doneddu</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Calcagno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ciammola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maderna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ticozzi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Castellani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beretta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rovaris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Verde</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Progressive motor neuron syndromes with single CNS lesions and CSF oligoclonal bands: never forget solitary sclerosis!</article-title>
            <source>Neurol Sci</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>6951</fpage>
            <page-range>6951-6954</page-range>
            <pub-id pub-id-type="pmid">36121546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Boggild</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Enevoldson</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Fletcher</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Myelopathy but normal MRI: where next?</article-title>
            <source>Pract Neurol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-102</page-range>
            <pub-id pub-id-type="pmid">18344379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tartaglia</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Findlater</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Orange</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Grace</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Strong</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.</article-title>
            <source>Arch Neurol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-6</page-range>
            <pub-id pub-id-type="pmid">17296839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Mitsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rowland</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>The natural history of primary lateral sclerosis.</article-title>
            <source>Neurology</source>
            <year>2006</year>
            <month>Mar</month>
            <day>14</day>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>647</fpage>
            <page-range>647-53</page-range>
            <pub-id pub-id-type="pmid">16534101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-164562.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Floeter</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Progression in primary lateral sclerosis: a prospective analysis.</article-title>
            <source>Amyotroph Lateral Scler</source>
            <year>2009</year>
            <season>Oct-Dec</season>
            <volume>10</volume>
            <issue>5-6</issue>
            <fpage>339</fpage>
            <page-range>339-46</page-range>
            <pub-id pub-id-type="pmid">19922121</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
